BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 6,782 Shares of argenex SE $ARGX

BNP PARIBAS ASSET MANAGEMENT Holding S.A. reduced its holdings in argenex SE (NASDAQ:ARGX) by 7.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 80,632 shares of the company’s stock after selling 6,782 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 0.13% of argenex worth $59,471,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Bessemer Group Inc. grew its position in shares of argenex by 276.5% in the 3rd quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock valued at $47,000 after purchasing an additional 47 shares during the period. Mather Group LLC. bought a new position in argenex in the third quarter valued at approximately $50,000. TD Private Client Wealth LLC boosted its holdings in shares of argenex by 750.0% in the third quarter. TD Private Client Wealth LLC now owns 85 shares of the company’s stock valued at $63,000 after buying an additional 75 shares during the period. MAI Capital Management boosted its holdings in shares of argenex by 866.7% in the second quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after buying an additional 78 shares during the period. Finally, Financial Consulate Inc. acquired a new position in argenex in the 3rd quarter worth $75,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Price Performance

Shares of argenex stock opened at $847.26 on Friday. The business has a fifty day simple moving average of $831.90 and a two-hundred day simple moving average of $804.81. argenex SE has a 1 year low of $510.05 and a 1 year high of $934.62. The company has a market capitalization of $52.43 billion, a price-to-earnings ratio of 36.38, a P/E/G ratio of 0.73 and a beta of 0.37.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ARGX. Royal Bank Of Canada lifted their price target on argenex from $860.00 to $925.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. TD Cowen lifted their target price on argenex from $800.00 to $1,146.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Zacks Research cut argenex from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 22nd. Citigroup reduced their price objective on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $1,000.00 target price on shares of argenex in a research report on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, argenex has an average rating of “Moderate Buy” and a consensus target price of $986.78.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.